
TY  - JOUR
TI  - Abstracts of the 8th Annual Meeting of the Societe Francaise de Pharmacologie, Strasbourg, 26-28 April 2004
JO  - Fundamental & Clinical Pharmacology
VL  - 18
IS  - 2
SN  - 0767-3981
UR  - https://doi.org/10.1111/j.1472-8206.2004.00250.x
DO  - doi:10.1111/j.1472-8206.2004.00250.x
SP  - 215
EP  - 268
PY  - 2004
ER  - 

TY  - JOUR
TI  - 2016 ACR/ARHP Annual Meeting Abstract Supplement
JO  - Arthritis & Rheumatology
JA  - Arthritis & Rheumatology
VL  - 68
IS  - S10
SN  - 2326-5191
UR  - https://doi.org/10.1002/art.39977
DO  - doi:10.1002/art.39977
SP  - 1
EP  - 4550
PY  - 2016
AB  - For a searchable version of these abstracts, please visit www.acrabstracts.org.
ER  - 

TY  - JOUR
TI  - Empowerment, Rights, and Ethics
JO  - Journal of Intellectual Disability Research
VL  - 56
IS  - 7‐8
SN  - 0964-2633
UR  - https://doi.org/10.1111/j.1365-2788.2012.01583_7.x
DO  - doi:10.1111/j.1365-2788.2012.01583_7.x
SP  - 717
EP  - 731
PY  - 2012
ER  - 

TY  - JOUR
TI  - Parenting with an Intellectual Disability
JO  - Journal of Intellectual Disability Research
VL  - 56
IS  - 7‐8
SN  - 0964-2633
UR  - https://doi.org/10.1111/j.1365-2788.2012.01583_9.x
DO  - doi:10.1111/j.1365-2788.2012.01583_9.x
SP  - 743
EP  - 748
PY  - 2012
ER  - 

TY  - JOUR
TI  - Third Annual Sickle Cell Disease Research and Educational Symposium and Grant Writing Institute and Annual National Sickle Cell Disease Scientific Meeting
JO  - American Journal of Hematology
JA  - Am. J. Hematol.
VL  - 84
IS  - 8
SN  - 0361-8609
UR  - https://doi.org/10.1002/ajh.21445
DO  - doi:10.1002/ajh.21445
SP  - E1
EP  - E235
PY  - 2009
ER  - 

TY  - JOUR
TI  - ABSTRACTS FROM PAPERS PRESENTED AT THE ANNUAL MEETING OF THE EUROPEAN ASSOCIATION OF VETERINARY DIAGNOSTIC IMAGING, BÄLSTA, SWEDEN, AUGUST 26–29, 1998
JO  - Veterinary Radiology & Ultrasound
VL  - 40
IS  - 2
SN  - 1058-8183
UR  - https://doi.org/10.1111/j.1740-8261.1999.tb01907.x
DO  - doi:10.1111/j.1740-8261.1999.tb01907.x
SP  - 183
EP  - 206
PY  - 1999
ER  - 

TY  - JOUR
TI  - Clinical care and other categories posters
JO  - Diabetic Medicine
JA  - Diabet. Med.
VL  - 31
IS  - s1
SN  - 0742-3071
UR  - https://doi.org/10.1111/dme.12378_2
DO  - doi:10.1111/dme.12378_2
SP  - 73
EP  - 183
PY  - 2014
ER  - 

TY  - JOUR
TI  - Physical Health
JO  - Journal of Intellectual Disability Research
VL  - 56
IS  - 7‐8
SN  - 0964-2633
UR  - https://doi.org/10.1111/j.1365-2788.2012.01583_10.x
DO  - doi:10.1111/j.1365-2788.2012.01583_10.x
SP  - 749
EP  - 765
PY  - 2012
ER  - 

TY  - JOUR
TI  - State of the Science Conference
JO  - Journal of Intellectual Disability Research
VL  - 56
IS  - 7‐8
SN  - 0964-2633
UR  - https://doi.org/10.1111/j.1365-2788.2012.01583_14.x
DO  - doi:10.1111/j.1365-2788.2012.01583_14.x
SP  - 813
EP  - 816
PY  - 2012
ER  - 

TY  - JOUR
TI  - Aging and Lifespan
JO  - Journal of Intellectual Disability Research
VL  - 56
IS  - 7‐8
SN  - 0964-2633
UR  - https://doi.org/10.1111/j.1365-2788.2012.01583_2.x
DO  - doi:10.1111/j.1365-2788.2012.01583_2.x
SP  - 658
EP  - 670
PY  - 2012
ER  - 

TY  - JOUR
TI  - Families
JO  - Journal of Intellectual Disability Research
VL  - 56
IS  - 7‐8
SN  - 0964-2633
UR  - https://doi.org/10.1111/j.1365-2788.2012.01583_8.x
DO  - doi:10.1111/j.1365-2788.2012.01583_8.x
SP  - 732
EP  - 742
PY  - 2012
ER  - 

TY  - JOUR
AU  - European Food Safety Authority (EFSA)
C7  - 1057
TI  - Safety and Nutritional Assessment of GM Plants and derived food and feed: The role of animal feeding trials
JO  - EFSA Journal
JA  - EFSA Journal
VL  - 6
IS  - 3
SN  - 1831-4732
UR  - https://doi.org/10.2903/j.efsa.2008.1057
DO  - doi:10.2903/j.efsa.2008.1057
SP  - 1057
PY  - 2008
ER  - 

TY  - JOUR
TI  - Special issue abstracts from the 34th annual meeting of the American Society for Apheresis, May 22–25, 2013 Denver, Colorado
JO  - Journal of Clinical Apheresis
JA  - J. Clin. Apheresis
VL  - 28
IS  - 2
SN  - 0733-2459
UR  - https://doi.org/10.1002/jca.21272
DO  - doi:10.1002/jca.21272
SP  - 87
EP  - 141
PY  - 2013
ER  - 

TY  - JOUR
TI  - Posters
JO  - FEMS Microbiology Letters
VL  - 222
IS  - s1
SN  - 0378-1097
UR  - https://doi.org/10.1016/S0378-1097(03)00297-0
DO  - doi:10.1016/S0378-1097(03)00297-0
SP  - 103
EP  - 505
PY  - 2003
ER  - 

TY  - JOUR
TI  - Cognition, Communication, Social Impairment
JO  - Journal of Intellectual Disability Research
VL  - 56
IS  - 7‐8
SN  - 0964-2633
UR  - https://doi.org/10.1111/j.1365-2788.2012.01583_5.x
DO  - doi:10.1111/j.1365-2788.2012.01583_5.x
SP  - 693
EP  - 702
PY  - 2012
ER  - 

TY  - JOUR
TI  - Profound Intellectual and Multiple Disabilites
JO  - Journal of Intellectual Disability Research
VL  - 56
IS  - 7‐8
SN  - 0964-2633
UR  - https://doi.org/10.1111/j.1365-2788.2012.01583_12.x
DO  - doi:10.1111/j.1365-2788.2012.01583_12.x
SP  - 785
EP  - 796
PY  - 2012
ER  - 

TY  - JOUR
TI  - Education and Employment
JO  - Journal of Intellectual Disability Research
VL  - 56
IS  - 7‐8
SN  - 0964-2633
UR  - https://doi.org/10.1111/j.1365-2788.2012.01583_6.x
DO  - doi:10.1111/j.1365-2788.2012.01583_6.x
SP  - 703
EP  - 716
PY  - 2012
ER  - 

TY  - JOUR
TI  - Plenary Presentations
JO  - Journal of Intellectual Disability Research
VL  - 56
IS  - 7‐8
SN  - 0964-2633
UR  - https://doi.org/10.1111/j.1365-2788.2012.01583.x
DO  - doi:10.1111/j.1365-2788.2012.01583.x
SP  - 655
EP  - 657
PY  - 2012
ER  - 

TY  - JOUR
TI  - Populations, Community, and Service Systems
JO  - Journal of Intellectual Disability Research
VL  - 56
IS  - 7‐8
SN  - 0964-2633
UR  - https://doi.org/10.1111/j.1365-2788.2012.01583_11.x
DO  - doi:10.1111/j.1365-2788.2012.01583_11.x
SP  - 766
EP  - 784
PY  - 2012
ER  - 

TY  - JOUR
TI  - Wednesday July 5, 2006 17:30–19:00 Hall 1 Schwarz Pharma & Valeant Pharmaceuticals International Satellite Symposium What's around the corner: AEDs in late development
JO  - Epilepsia
VL  - 47
IS  - s3
SN  - 0013-9580
UR  - https://doi.org/10.1111/j.1528-1167.2006.00715_90.x
DO  - doi:10.1111/j.1528-1167.2006.00715_90.x
SP  - 272
EP  - 272
PY  - 2006
AB  - 1 E. Ben-Menachem ( 1 Neurologkliniken, Sahlgrenska Universitetssjukhuset, Goteberg, Sweden ) Lacosamide is in Phase 3 of clinical development for the adjunctive treatment of epilepsy and neuropathic pain. Currently the mode of action (MOA) is under investigation since it has been previously demonstrated that lacosamide does not share a MOA with other currently marketed antiepileptic drugs (AEDs). The drug can be administered orally or intravenously. Results from pharmacokinetic studies suggest that lacosamide has a low potential for drug-drug interactions, and it appears that lacosamide has a minimal risk for affecting the pharmacokinetics of commonly prescribed concomitant AEDs for the treatment of epilepsy. In a double-blind, randomized, placebo-controlled, multicenter trial for the treatment of partial seizures (SP667), lacosamide was administered orally in doses of 200 mg, 400 mg and 600 mg divided in 2 daily doses. In this trial, lacosamide demonstrated a statistically significant reduction in seizure frequency over placebo. Moreover, the 50% responder rate (defined as patients with at least a 50% reduction in seizure frequency) was statistically significant. A further trial (SP616) investigated the safety, tolerability and pharmacokinetics of IV lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. The nature of AEs reported following 60- and 30 minute infusions of lacosamide was consistent with AEs reported following oral administration of lacosamide. Dose-related adverse events include dizziness, nausea, fatigue, ataxia, vision abnormal, diplopia, and nystagmus. The currently available results justify the further development of lacosamide for the treatment of epilepsy.
ER  - 
